| scholarly article | Q13442814 |
| P2093 | author name string | Wei Liu | |
| Yinghao Yu | |||
| Shunping Chen | |||
| Jinhua Tu | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| The ErbB signaling network: receptor heterodimerization in development and cancer | Q29617919 | ||
| Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? | Q30856729 | ||
| HER 2/neu protein expression in colorectal cancer | Q33242725 | ||
| HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 | ||
| Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas | Q33943812 | ||
| Interpretation and quantification of immunostains | Q34425790 | ||
| Vaccination against the HER-2/neu oncogenic protein | Q34577222 | ||
| The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. | Q35055207 | ||
| HER-2/neu evaluation in breast cancer are we there yet? | Q35857573 | ||
| c-erbB-2 is not a major factor in the development of colorectal cancer | Q36644043 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| Expression of HER2 in colorectal cancer does not correlate with prognosis | Q37329191 | ||
| Lessons learned from independent central review | Q37356175 | ||
| The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters | Q38449317 | ||
| Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry | Q38463502 | ||
| KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. | Q39861972 | ||
| Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo | Q39865068 | ||
| HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. | Q40291966 | ||
| Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth | Q43619428 | ||
| Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial | Q45217739 | ||
| EGFR, HER-2 and COX-2 levels in colorectal cancer | Q46186653 | ||
| Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations | Q46211466 | ||
| Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer | Q46228685 | ||
| Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays | Q47430147 | ||
| Clinical role of HER-2/neu expression in colorectal cancer. | Q51046708 | ||
| HER-2/neu in breast cancer: a comparative study between histology, immunohistochemistry, and molecular technique (FISH). | Q51176540 | ||
| Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. | Q51789617 | ||
| Evaluating HER2 amplification and overexpression in breast cancer. | Q52936177 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| Clinico-Pathological and Prognostic Significance of p53, Bcl-2 and Her-2/neu Protein Markers in Colorectal Cancer Using Tissue Microarray. | Q53317073 | ||
| Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. | Q53593820 | ||
| HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients. | Q54551877 | ||
| Heterogenous high-level HER-2 amplification in a small subset of colorectal cancers. | Q54660628 | ||
| The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer | Q73212054 | ||
| TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer | Q73833118 | ||
| The prognostic value of invariant chain (Ii) and Her-2/neu expression in curatively resected colorectal cancer | Q74325369 | ||
| HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors | Q75209089 | ||
| Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas | Q79800177 | ||
| Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer | Q79866807 | ||
| The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study | Q81050108 | ||
| Her-2/neu over-expression correlates with more advanced disease in Iranian colorectal cancer patients | Q81449309 | ||
| Over-expression of Her-2 in colorectal cancer tissue, but not in serum, constitutes an independent worse prognostic factor | Q86876904 | ||
| P433 | issue | 1 | |
| P921 | main subject | colorectal cancer | Q188874 |
| Erb-b2 receptor tyrosine kinase 2 | Q415271 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 17-24 | |
| P577 | publication date | 2014-11-11 | |
| P1433 | published in | Experimental and Therapeutic Medicine | Q23979083 |
| P1476 | title | Significance of human epidermal growth factor receptor 2 expression in colorectal cancer | |
| P478 | volume | 9 |
| Q37290538 | Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer |
| Q38384113 | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study |
| Q92838804 | Correlation of HER2 and FOXM1 in human colorectal carcinoma and its clinical significance |
| Q57183898 | Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status |
| Q37708897 | HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q37406381 | Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer |
| Q61816598 | Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib |
| Q90402443 | lncRNA PDIA3P regulates cell proliferation and invasion in non-small cell lung cancer |
Search more.